Summary During a 15-month period, we used in vivo bromodeoxyuridine (BUDR) 
Since the mid 1960s investigators have been attracted by the possibility that cell kinetics could be a parameter for cancer prognosis and chemotherapy planning. For example, rapidly growing tumours are expected to run a more rapid course without treatment, but to be more sensitive to cell cycledependent agents than slowly growing ones.
Gross differences in proliferative activity are known to exist among various human tumours (Bauer et al., 1986; Hoshino et al., 1986a; Montecucco et al., 1983; Riccardi et al., 1986a; Silvestrini et al., 1977 Silvestrini et al., , 1985 . For example, high malignancy non-Hodgkin's lymphomas usually proliferate more rapidly than acute leukaemias (AL) and multiple myeloma. Unfortunately, substantial overlap occurs, and the kinetic characteristics are largely unpredictable in the individual patient.
Greater insight into this topic has been sharply limited by the fact that the direct measurement of cell kinetics is not easy in clinical settings. Evaluating the simplest proliferative parameter, i.e. the S phase size, traditionally requires tritiated thymidine (3H-TdR) cytoautoradiography (to obtain the 3H-TdR labelling index, LI), or DNA flow cytofluorometry (FCM) (for the percentage of cells with DNA content intermediate between the diploid, 2n, and the tetraploid, 4n, values: 2n-4n cell %). However, cytoautoradiography is time consuming and, with FCM, the S phase is not evaluable when the tumour is aneuploid, or it is overestimated when S-phase arrested cells (U-cells) De Fazio et al., 1987) are present. Furthermore, S-phase size alone gives only a partial picture of tumour kinetics, for which a wider experimental panel of kinetic parameters, including the duration of the cell cycle and of its phases, is necessary. Methods for obtaining these temporal data are exceedingly difficult to apply in humans (Steel, 1977) .
The in vivo administration of bromodeoxyuridine (BUDR, a non-radioactive pyrimidine analogue which is incorporated into S-phase cells) coupled with bivariate FCM for measurements (Wilson et al., 1985) allows a complete kinetic picture of human cancer to be obtained easily, using a single tumour sample taken 6h after BUDR infusion and double stained with a green fluorescent anti-BUDR monoclonal antibody and a red fluorescent DNA dye (Begg et al., 1985; Danova et al., 1987a; Riccardi et al., 1988 Table I ). Two to 4 mm diameter tumour samples were obtained during surgery in patients with gastric and brain tumours. Histologically normal gastric mucosa was obtained from seven patients with gastric cancers (Table II) . Sample processing The complete procedure for obtaining single cell suspensions for FCM from tissue samples has been detailed elsewhere (Riccardi et al., 1988 ethanol at a concentration not exceeding 1 x 106 cells ml-1.
BUDR and DNA staining and bivariate flow cytometry BUDR detection (Wilson et al., 1985; Danova et al., 1987b) basically involves double stranded DNA denaturation with 2N HCl, allowing the anti-BUDR MoAb to react with BUDR in the DNA chain (Gratzner, 1982; Moran et al., 1985) , which is then visualised by means of a standard immunofluorescence technique. Briefly, cell suspensions were first incubated with 2NHCl (for 30min at 37°C) and about 1 x 106 of these cells were later suspended in 1 ml of PBS containing 0.5% Tween-20 and 0.5% normal goat serum (NGS) for 15 min at 37°C, washed in PBS, and then incubated in 0.5 ml of PBS containing and IOpl of the anti-BRDU MoAb (Becton Dickinson, Lab Impex Ltd, Twickenham, Middlesex, UK) for 30 min at room temperature with occasional mixing. Following two washings in PBS, the cells were resuspended in 1 ml of PBS containing Tween-20 and NGS for 15 min, and later with the second antibody (10 p1 of goat anti-mouse IgG FITC conjugate, Sigma Chemicals), in 0.5 ml of PBS/Tween-20/ NGS for 30min. For DNA staining, these cells were further washed two times in PBS and resuspended in 4 ml PBS containing 10 pg ml -propidium iodide (PI) (which stochiometrically stains DNA) for 15min.
Bivariate distributions of BUDR labelling (green) versus DNA content (red) were measured using an Ortho System 50-M Cytofluorograph (Ortho Instruments, Westwood, MA, USA) (Wilson et al., 1985) , and the data, collected in the list mode, were analysed using an Ortho 2150 computer. An appropriate window was used to eliminate debris, cell doublets, triplets, etc., from the analysis. The window was chosen by gating the cytogram of the distributions of DNA values versus cell area. For each specimen 20,000-50,000 cells were analysed.
DNA histograms were constructed with the same instrumentation. Normal BM and normal gastric mucosa and brain cells (obtained at surgery for head injuries) were used as diploid reference standard, for AL and gastric and brain cancers, respectively. Aneuploidy was estimated from the DNA index, i.e. the ratio between the modal channel of the GO/I peak of the tumour population and the modal channel of the GO/I peak of the reference standard. In cases with unimodal DNA distribution, the percentages of cells with 2n (GO/I phase), 4n (G2 and mitotic phases) and 2n-4n (S phase) DNA content were determined as previously described (Wilson et al., 1985) .
Evaluation of BUDR-LI and TS
Both the LI and TS were assessed on cell samples taken 4-6 h after completion of the 1 h BUDR infusion. This procedure (Begg et al., 1985) basically involves the assumption that at the time of BUDR infusion the mean DNA content of BUDR-labelled S-phase cells is in the middle of the interval between the 2n (GO/1) and 4n (G2) peaks (Figure la) and that the rate of cell progression through the S phase is constant. At the time of tumour sampling, i.e. 4-6 h later, the S phase cells (which were labelled with BUDR at the time of its infusion) have moved toward G2 at a rate that is dependent on their TS. On the 4-6h cytogram their peak DNA content distribution appears as shifted toward 4n, and some cells have recycled to GO/I following mitosis, in that they are found as labelled cells with 2n DNA content ( Figure  1 b) .
From these 4-6 h cytograms the LI value is established as the percentage, over the whole population, of the S phase cells plus half the percentage of the 2n BUDR-labelled cells. The TS is calculated by measuring the position of the BUDR-labelled S phase cells from their mean DNA content. This measure allows one to determine the rate at which they have progressed though the S phase in the interval between BUDR infusion and tumour sampling. All S phase cells are expected to have reached G2 at a time corresponding to TS, which can be calculated from this progression rate.
Calculated cell kinetic parameters
Once the LI and TS were experimentally obtained from BUDR incorporation analysis, two additional kinetic parameters were calculated, namely the potential doubling time (Tpot) and the cell production rate (FTR).
For these calculations a steady state condition (Steel, 1977) was arbitrarily assumed. The Tpot is hence calculated by the formula:
The reciprocal is the FTR:
FTR(cells/100 cells/day) = (LI/TS) x 24
Clinical and pathological data Thirty-four of the 50 patients with AL had untreated acute non-lymphoblastic leukaemia (AnLL) ( Berkson & Gage (1950) .
Results
The results obtained are summarised in Figure 1 and in Tables I and II Table I ).
-40 sample taken immediately after BUDR infusion), the position of the BUDR-labelled cells is shifted to the right. In the 6 h interval between BUDR infusion and tumour sampling, cells have in fact moved through S phase and some have already recycled (they appear with a diploid DNA content in the cytogram).
The Correlations between kinetic and pathological data Tables I and II summarise what kinetic differences were found in accordance with the above mentioned pathological and clinical patient characteristics. Obviously, the kinetic data concern only patients who had successful determination of both LI and TS.
The 20 responsive AnLL patients had a shorter Tpot and greater FTR than the 14 non-responsive ones, due to a significantly shorter TS (Table I) . Responsive patients who experienced CR>8 months had proliferative activity higher than those with shorter CR, mainly due to higher LI values.
Proliferative activity was greater in 11 patients with advanced gastric cancers than in 10 with more limited disease, and this was mainly accounted for by differences in LI. No differences in proliferative activity were found to be dependent on histology and DNA ploidy, and no correlations were found between proliferative activity and local or distant tumour recurrence and patient survival.
In malignant brain tumours median values for LI, TS, Tpot and FTR were, respectively, 6.4 (range: 3.1-10.1)%, 14.8 (9.8-22.7)h, 12.1 (6.0-26.8) days and 9.7 (3.7-16.4) cells per 100 cells per day. No differences in clinical behaviour were found depending on any of the above mentioned parameters.
Discussion
In this study, administering BUDR to patients and employing bivariate FCM to measure simultaneously BUDR incorporation and DNA content has allowed a complete panel of kinetic parameters to be obtained for several human tumours in a short time, while using only one tumour sample. This indicates that this method can be used to evaluate the proliferative behaviour of neoplasias in clinical settings. Some correlations between kinetic and clinical data were also obtained.
In a preceding paper (Riccardi et al., 1988) we thoroughly discussed the advantages of using the in vivo BUDR method for studying cell kinetics in a variety of human tumours, and will briefly summarise them here. The first reason favouring this over the traditional cytokinetic methods is that it furnishes an S phase evaluation which is easier and more accurate than that obtained from both 3H-TdR cytoautoradiography and DNA FCM. With respect to 3H-TdR cytoautoradiography the in vivo BUDR procedure is more rapidly accomplished and a much greater number of cells is evaluated. With respect to DNA FCM, an accurate estimation of the S phase can be obtained in both aneuploid tumours (no mathematical model allows this from the simple DNA histogram) and in tumours where a number of 2n-4n BUDR unlabelled cells (U-cells) De Fazio et al., 1987) exist. A second advantage of the in vivo BUDR method is that it also furnishes the rate at which proliferating cells synthesise DNA, i.e. the TS, a parameter which is exceedingly difficult to obtain with the traditional techniques (Steel, 1977) . With in vivo BUDR the TS is simply evaluated from measuring the degree of the progression rate toward G2 of the BUDR-labelled cells in the interval (4-6h) between BUDR infusion and tumour sampling (Figure 1 ), assuming that cell progression through the S phase is constant (Begg et al., 1985) . The TS values we obtained were strictly related to those drawn, on duplicate samples, from quantitative 14C-TdR cytoautoradiography (Riccardi et al., 1988) , which is an accepted method for calculating TS. From the experimentally obtained LI and TS, a number of temporal kinetic parameters can be calculated (Dormer, 1973; Steel, 1977; Ucci et al., 1985) , assuming either a steady state or other more complex models for cell proliferation (Steel, 1977) . We calculated the Tpot, i.e. the time in which the whole tumour duplicates, and the FTR, i.e. its rate of cell production, as the most meaningful for giving an overall picture of tumour growth.
The major advantage of the in vivo BUDR procedure is, however, that it is feasible in clinical settings. There are no reports of immediate adverse reactions following BUDR infusion; only one tumour sample is required for the study, and this is needed anyway for diagnostic or therapeutic purposes. The whole procedure takes 8-9h from the start of BUDR infusion and only 2-3h from the tumour sampling. In this way we were able to investigate quite a large number of consecutive patients in a 15-month period, obtaining accurate LI values in over two-thirds of the cases and TS, Tpot and FTR values in over half (Riccardi et al., 1988) . There are other rapidly progressing clinical studies with in vivo BUDR which employ FCM or immunohistochemistry for detecting the BUDR-labelled cells. They include very large series of AL and chronic myelogenous leukaemia (Raza et al., 1987) , malignant and benign brain tumours (Cho et al., 1986; Hoshino et al., 1985 , b Danova et al., 1988a Nagashima et al., 1986) , gastric (Dionigi et al., 1988; Danova et al., 1988b) and ovarian cancers (Erba & Mangioni, unpublished data) as well as miscellaneous tumours (Riccardi et al., 1988; Wilson et al., 1989) . For solid neoplasias a long-discussed possibility is that kinetic parameters change in different areas of the tumour, so that the proliferative characteristics obtained may not be representative of overall tumour kinetics.. In vivo BUDR incorporation analysis has permitted us to begin investigating this point. We examined six patients with gastric tumours who had had LI and TS measured on two different tumour samples, and the intratumoral kinetic variation was not great (Riccardi et al., 1988) .
In the present study a preliminary attempt was made to correlate kinetic with clinical data in cases who had both LI and TS determinations. In 34 uniformly treated AnLL patients proliferative activity, as measured from Tpot and FTR, was greater in responsive than in non-responsive cases and in those who experienced CR for over 8 months than in those who had a shorter CR, suggesting that high proliferative activity is a favourable prognostic factor in this disease. We believe that these data on AL are of true clinical relevance. For many years investigators have tried to evaluate the clinical interest of proliferative activity in previously untreated AL by evaluating the S phase with 3H-TdR cytoautoradiography or DNA FCM. A number of them reported that CR was more frequent with high S phase values; others failed to confirm this finding but none reported an advantage with low S phase values (Riccardi et al., 1986a) . In this series LI was not different in responsive and non-responsive patients, but the responsive ones had a shorter Tpot and greater FTR due to a shorter TS. A response advantage for AL patients with shorter TS was also reported using the 3H-and 14C-TdR double labelling technique (Paietta et al., 1980) or in vivo BUDR coupled with im-munohistochemistry (Raza et al., 1985 (Raza et al., , 1987 . From these data the concept that a high proliferative activity favours CR in AnLL, due to a high S phase value and/or a short TS, can be accepted. Of course, the prognostic significance of proliferative activity must be better ascertained from the multivariate analysis of other clinical and laboratory features. The in vivo BUDR method allows one to include kinetic behaviour in this analysis.
No literature reports exist on the in vivo kinetic characteristics of gastric cancers. The distinctly greater proliferative activity in advanced (stage IV) disease could suggest that high proliferative activity favours tumour progression. Correlations with treatment results were not expected since our series is too small to account for the large number (histology, DNA ploidy, clinical stage at diagnosis, palliative or radical surgery, local or distant tumour recurrence) influencing treatment outcome in this disease.
We conclude that the cell kinetics of human tumours can be reliably studied in clinical settings by combining in vivo BUDR administration and FCM measurements of BUDR incorporation and DNA content. In prospective investigations the prognostic meaning of proliferative activity and its usefulness in planning antitumour treatments can be ascertained.
